MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 3, 2008, Pages 573-577

  Boot, J D ^a   De Haas, S L ^a   Van Gerven, J M A ^a   De Smet, M ^b   Leathem, T ^b   Wagner, J ^c   Denker, A ^c   Miller, D ^c   Van Doorn, M B A ^a   Schoemaker, R C ^a   Cohen, A F ^a   Diamant, Z ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Merck Clinical Pharmacology   (Belgium)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Interaction; MK 0873; Pharmacokinetics; Theophylline

Indexed keywords

MK 0873; PHOSPHODIESTERASE IV INHIBITOR; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEMATOMA; HOT FLUSH; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; ORAL PARESTHESIA; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; NAPHTHYRIDINES; PHOSPHODIESTERASE INHIBITORS; THEOPHYLLINE; THERAPEUTIC EQUIVALENCY;

EID: 43049135501     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.01.009     Document Type: Article

References (14)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report, Bethersda/Martyland, 1995; Last updated 2006.
2. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
3. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., and Barnes P.J. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natt Aacd Sci 99 (2002) 8921-8926
4. Barnes P.J. Current therapies for asthma. Promise and limitations. Chest 111 (1997) 17S-26S
5. Cheer S.M., and Scott L.J. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 1 (2002) 285-300
6. Shah L., Wilson A.J., Gibson P.G., and Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev (2003) (CD001281)
7. Jarvis B., and Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages
8. Reed C.E., Offord K.P., Nelson H.S., Li J.T., and Tinkelman D.G. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American academy of allergy, asthma, and immunology beclomethasone dipropionate-theophylline study group. J Allergy Clin Immunol 101 (1998) 14-23
9. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 (1998) 351-370
10. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-75.
11. Sturton G., and Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD*. Chest 121 (2002) 192S-196S
12. Vignola A.M.A. PDE4 inhibitors in COPD-a more selective approach to treatment. Respir Med 98 (2004) 495-503
13. Murdoch R.D., Zussman B., Schofield J.P., and Webber D.M. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. J Clin Pharmacol 44 (2004) 1046-1053
14. Holstad S.G., Perry P.J., Kathol R.G., Carson R.W., and Krummel S.J. The effects of intravenous theophylline infusion versus intravenous sodium bicarbonate infusion on lithium clearance in normal subjects. Psychiatry Res 25 (1988) 203-211